H1 2025 Results
Ipsen’s financial results for the first half of 2025 will be published on 31 July 2025 at 07:00 CET.
An investor and analyst conference call will follow at 13:00 CET.
About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries, and our partnerships around the world, enable us to bring medicines to patients in more than 100 countries.
Ipsen in brief
Discover Ipsen in 3 pages; our medicines and key figures, our objectives and our strategy.
If you are experiencing difficulties registering for the investor and analyst conference call, please contact: khalid.deojee@ipsen.com
Key contacts
-
Khalid Deojee
Responsable Principal, Relations Investisseurs
Résultats S1 2025
Ipsen publie ses résultats pour l’exercice 2022 et le quatrième trimestre 2022 – Un mot du Directeur général d’Ipsen, David Loew
Un mot de David Loew, Directeur Général
Un mot de David Loew, Directeur Général